Fresh analysis reveals that people who discontinue blockbuster slimming jabs like semaglutide or tirzepatide tend to recover shed pounds far faster than those who stop conventional lifestyle programs.
Research printed in a prominent medical journal shows that while overweight people frequently drop substantial amounts of their body weight while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"Users purchasing these medications must be cognizant of the danger of rapid rebound weight gain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.
That rate of regain implies a return to starting weight in about a year and a half.
Analyzing Therapies
The study, which looked at dozens of trials involving over 9,000 of patients, contrasted the outcomes of GLP-1 agonists with older methods.
Scientists emphasize that people who lose weight through diet and exercise usually see a more gradual creep back—around 0.1 kg a month—once they finish.
Explaining the Fast Rebound
Experts propose the way of the jabs accounts for the heightened weight return.
The injections copy a natural hormone called GLP-1, which moderates feelings of fullness.
"Sustained high doses of the hormone concentrations several times higher than normal might result in the body to produce less of its own natural GLP-1, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics expert.
"Stopping of this GLP-1 'fix' means appetite is no longer kept in check, making binge eating a significant risk."
A Chronic Disease?
The NHS recommend the injections for people with weight-linked health risks, alongside recommended diet and exercise modifications.
Many experts say that, due to the likelihood of weight regain, the therapy might need to be ongoing.
This opinion is echoed by pharmaceutical companies, who say that the results "emphasize the persistent nature of excess weight," similar to managing conditions like high blood pressure.
Patient Experiences
People who have stopped the jabs report a intense return of hunger.
"It felt as if something that goes on and you're instantly starving," said a patient.
This challenge is worsened if individuals have not established permanent dietary or behavioural modifications during treatment.
Significant Interest
Recent estimates suggest that a significant number of people in the UK have tried these injections in the last 12 months, with interest being substantial.
- Use is more common among women compared to men.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion access the drugs through private healthcare rather than the NHS.
Ultimately, researchers stress that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone solution and maintained weight loss likely depends on combined behavioural changes.
